Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 15/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578439 | 0.86 | CXCR3 (0.40) | CXCR3HTTSMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL3587157 | 0.86 | CXCR3 (0.41) | CXCR3LMNAHTTALDH1A1TP53 | |
| SCHEMBL13031306 | 0.85 | GRIN1 (0.46) | CXCR3LMNAHTTALDH1A1TP53 | |
| SCHEMBL3582567 | 0.85 | MAPT (0.39) | LMNAALDH1A1TP53 | |
| SCHEMBL3588834 | 0.84 | GRIN1 (0.35) | LMNAALDH1A1GRIN1GRIN2B | |
| SCHEMBL3589593 | 0.84 | LMNA (0.40) | CXCR3LMNAHTTALDH1A1TP53 | |
| SCHEMBL3581098 | 0.83 | CPT1A (0.33) | LMNAALDH1A1SMN1; SMN2GRIN1GRIN2B | |
| SCHEMBL3580754 | 0.82 | GABRA1 (0.34) | LMNAALDH1A1GRIN1GRIN2B | |
| SCHEMBL3593480 | 0.82 | CPT1A (0.35) | ALDH1A1 | |
| SCHEMBL3592264 | 0.82 | CPT1A (0.33) | LMNAALDH1A1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885LMNA 4877/4885HTT 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.